Supply / Manufacturing · Global (LMICs) · Announced 27 Oct 2026
Adalvo → SinoPep
Adalvo and China's SinoPep form a GLP-1 and oligonucleotide (TIDES) API supply and co-development partnership — securing the upstream peptide and oligonucleotide backbone behind Adalvo's global and MENA GLP-1 pipeline.
Parties: Adalvo (Switzerland) → SinoPep (Sinopep-Allsino Biopharmaceutical) (China)
- Deal type
- Supply / Manufacturing
- Value
- Undisclosed
- Territory
- Global API supply and co-development
- Therapeutic area
- Metabolic / Diabetes
- Asset
- GLP-1 and oligonucleotide (TIDES) APIs
- Announced
- 27 Oct 2026
Our analysis
Why this matters
Adalvo, the Zug-based B2B generics and GLP-1 leader, and SinoPep (Sinopep-Allsino Biopharmaceutical), a Chinese peptide and oligonucleotide (TIDES) API and CDMO specialist, have established a strategic partnership spanning GLP-1 and oligonucleotide therapeutics — securing API supply and co-development across two of the hardest-to-manufacture modalities.
The full analysis is free to read with a work email on this page.
Source: SinoPep